Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Sunitinib). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Sunitix 37.5 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended Dose for GIST and Advanced RCC: The recommended dose of Sutinib for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is one 50 mg oral dose taken once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). It may be taken with or without food. Recommended Dose for Adjuvant Treatment of RCC: The recommended dose of Sutinib for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. It may be taken with or without food. Recommended Dose for pNET: The recommended dose of Sutinib for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily continuously without a scheduled off-treatment period. It may be taken with or without food.
Side Effects
The most common side effects are hepatotoxicity, cardiovascular events, QT interval prolongation and torsade de pointes, hypertension, hemorrhagic events, tumor lysis syndrome (TLS), thrombotic microangiopathy, proteinuria, dermatologic toxicities, thyroid dysfunction, hypoglycemia, osteonecrosis of the jaw (ONJ), and impaired wound healing.
Cautions & Contraindications
Contraindications
Sunitinib should not be used in people who have a known allergy (hypersensitivity) to Sunitinib or to any of the other ingredients in this product.